secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001753926-25-000438
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani plans Cortigent spin-off, reports $18.4M cash; LIBERATE-1 trial fully enrolled with first implant
--------------------------------------------------------------------------------

- Spin-off of Cortigent into independent public company planned by mid-2025; expects tax-free distribution to Vivani shareholders.
- Cortigent's Orion artificial vision device completed 6-year study; Argus II previously FDA-authorized for blindness.
- LIBERATE-1 trial of GLP-1 implant NPM-115: first implant administered, all 24 subjects enrolled in 4 weeks; top-line data expected mid-2025.
- Preliminary cash and cash equivalents (excluding restricted) as of Dec 31, 2024: $18.4M (unaudited).
- ThinkEquity LLC acting as financial advisor to Cortigent for spin-off.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625000438/0001753926-25-000438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625000438/vani-20250313.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer